Detecting Ovarian Cancer Early; Allergy Med for NSCLC? Bad News for Anti-TIGIT Drug

Derick Alison
Derick Alison
3 Min Read

It may be possible to detect ovarian cancer years in advance of actual symptom onset based on the molecular and genetic analysis of cells taken from routine Pap tests. (Science Translational Medicine)

A six-patient clinical trial involving non-small cell lung cancer (NSCLC) patients suggested that combining immunotherapy with dupilumab (Dupixent) — an interleukin-4/13 inhibitor widely used to treat allergic conditions such as eczema and asthma — may boost the anti-cancer immune response. (Nature)

Rep. Glenn Thompson (R-Pa.) announced he has been diagnosed with prostate cancer. (The Hill)

Artificial intelligence could help boost the Biden administration’s cancer moonshot goals. (Politico)

Liver elastography can be an effective and non-invasive method of predicting the risk of liver cancer in patients with cirrhosis secondary to chronic hepatitis C. (Clinical Gastroenterology and Hepatology)

A New Jersey medical student is undergoing treatment for papillary thyroid cancer discovered when she was in a class learning how to perform ultrasounds. (ABC News)

The U.S. Air Force is expanding its study on the high rates of cancers reported in service members who worked with nuclear missiles. (ABC News)

Sanofi said its phase III IMROZ study in transplant-ineligible patients with newly diagnosed multiple myeloma met its primary endpoint, showing that the addition of isatuximab (Sarclisa) to bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone improved progression-free survival (PFS) versus the standard three-drug regimen alone.

Nivolumab (Opdivo) plus ipilimumab (Yervoy) improved PFS versus chemotherapy in metastatic colorectal cancer patients with microsatellite instability-high or mismatch repair-deficient disease in an interim analysis of the CheckMate-8HW trial, Bristol Myers Squibb announced.

Roche announced that a phase III trial testing first-line treatment in PIK3CA-mutated, hormone-receptor positive/HER2-negative breast cancer met its primary endpoint, with the investigational PI3K alpha inhibitor inavolisib improving PFS when combined with palbociclib (Ibrance) and fulvestrant (Faslodex).

Meanwhile, Merck said that in previously metastatic NSCLC, its anti-TIGIT drug vibostolimab failed to significantly extend PFS or improve overall survival when added to pembrolizumab (Keytruda) in a phase II study.

  • author['full_name']

    Mike Bassett is a staff writer focusing on oncology and hematology. He is based in Massachusetts.

Source link

Share this Article
Leave a comment
adbanner